vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report issued on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners initiated coverage on vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Stock Down 0.3 %

VTVT opened at $17.15 on Thursday. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $29.19. The company has a fifty day moving average of $17.26 and a 200-day moving average of $15.50. The stock has a market cap of $54.71 million, a PE ratio of -3.79 and a beta of 1.07.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.32. The firm had revenue of $0.02 million for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC acquired a new stake in shares of vTv Therapeutics in the 3rd quarter valued at about $2,402,000. JPMorgan Chase & Co. bought a new position in vTv Therapeutics in the fourth quarter worth approximately $25,000. Finally, Geode Capital Management LLC grew its stake in vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the period. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.